New chemo cocktail aims to stop colon Cancer's return
NCT ID NCT05179889
First seen Mar 30, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This trial compares two chemotherapy combinations after surgery for people with high-risk stage III colon cancer. About 308 participants will receive either mFOLFIRINOX or the standard mFOLFOX6 for 12 cycles. The goal is to see if the stronger combo delays cancer recurrence and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chungnam National University Hospital
RECRUITINGDaejeon, 34112, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy (irinotecan, oxaliplatin, leucovorin, 5-FU)
What this could lead to
If successful, this could show that a stronger chemo combo (mFOLFIRINOX) helps prevent colon cancer from coming back after surgery better than the current standard.
What could go wrong
This is a mid-stage trial, so results are not yet proven. The stronger chemo may cause more side effects, and it may not improve survival or recurrence rates.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.